Cytomegalovirus (CMV): Epidemiology Forecast to 2027

Cytomegalovirus (CMV): Epidemiology Forecast to 2027

  • June 2018 •
  • 55 pages •
  • Report ID: 5476639 •
  • Format: PDF
Cytomegalovirus (CMV): Epidemiology Forecast to 2027

Summary
The report "Cytomegalovirus (CMV): Epidemiology Forecast to 2027", report provides an overview of the risk factors, comorbidities, and global and historical trends for Cytomegalovirus (CMV) disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).

Cytomegalovirus (CMV) is a common virus belonging to the Herpesviridae family.CMV is present in up to 60% of adults in high-income countries and up to 100% of adults in low- and middle-income countries.

In individuals with healthy immune systems, Cytomegalovirus (CMV) infections are typically asymptomatic, and the virus establishes a lifelong latent infection.Certain populations, such as people living with human immunodeficiency virus (HIV), solid organ transplant (SOT) patients, allogeneic hematopoietic stem cell transplant (allo-HSCT) patients, and infants infected in utero, are vulnerable to symptomatic disease caused by primary CMV infections or reactivation.

CMV disease may also occur in critically ill immunocompetent patients (Siciliano et al., 2014). Depending on the population, CMV disease can present as end-organ disease (infection and symptoms in lung, gastrointestinal (GI) tract, liver, retina, or other organs), CMV syndrome (fever, fatigue, leukopenia, and/or thrombocytosis), or congenital CMV (cCMV) (symptoms ranging from mild manifestations to premature birth and neurologic sequelae.

In 2017, there were 9,691 diagnosed incident cases of Cytomegalovirus (CMV) disease in the 7MM.The US had the most cases (5,885), while Japan had the fewest (271).

Epidemiologists forecast that the number of CMV cases in the 7MM will increase to 10,704 in 2027, at an Annual Growth Rate (AGR) of 1.05%. All countries besides Germany are expected to see an increase in CMV cases. HIV patients made up the greatest burden of CMV cases in the 7MM in 2017 (3,734 cases), followed closely by SOT patients (3,696 cases).cCMV accounted for the fewest cases (979).

The report includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0-10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM.

Scope
- The Cytomegalovirus (CMV) Epidemiology Forecast Report provides an overview of the risk factors and global trends of CMV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report provides an overview of the risk factors, comorbidities, and global and historical trends for CMV disease among HIV, SOT, allo-HSCT, and newborn populations in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for diagnosed incident cases of CMV disease segmented by population at risk, sex, and age (in 10-year age groups beginning at ages 0-10 years and ending at ages 80 years and older) in these markets. In addition, this report includes a 10-year forecast for SOT and allo-HSCT patient populations in the 7MM.
- The CMV epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The CMV Epidemiology Forecast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CMV market.
- Quantify patient populations in the global CMV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CMV therapeutics in each of the markets covered.
- Understand magnitude of CMV population by population at risk.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.